264 related articles for article (PubMed ID: 32354772)
1. Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.
Duret PM; Sebbag E; Mallick A; Gravier S; Spielmann L; Messer L
Ann Rheum Dis; 2020 Sep; 79(9):1251-1252. PubMed ID: 32354772
[No Abstract] [Full Text] [Related]
2. Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina
Duret PM; Spielmann L; Messer L
Ann Rheum Dis; 2021 May; 80(5):e80. PubMed ID: 32816687
[No Abstract] [Full Text] [Related]
3. [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Malek SA; Bouchti IE
Pan Afr Med J; 2020; 35(Suppl 2):134. PubMed ID: 33193949
[TBL] [Abstract][Full Text] [Related]
4. Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.
Messina F; Pampaloni F; Piaserico S
Ann Rheum Dis; 2021 May; 80(5):e79. PubMed ID: 32816688
[No Abstract] [Full Text] [Related]
5. TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
Chen XY; Yan BX; Man XY
Ther Adv Respir Dis; 2020; 14():1753466620926800. PubMed ID: 32436460
[TBL] [Abstract][Full Text] [Related]
6. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Coskun Benlidayi I; Kurtaran B; Tirasci E; Guzel R
Rheumatol Int; 2020 Oct; 40(10):1707-1716. PubMed ID: 32591970
[TBL] [Abstract][Full Text] [Related]
7. Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report.
Lee JM; Lee SJ
J Korean Med Sci; 2020 Jun; 35(21):e201. PubMed ID: 32476306
[TBL] [Abstract][Full Text] [Related]
8. Biologics, spondylitis and COVID-19.
Rosenbaum JT; Hamilton H; Choi D; Weisman MH; Reveille JD; Winthrop KL
Ann Rheum Dis; 2020 Dec; 79(12):1663-1665. PubMed ID: 32522741
[No Abstract] [Full Text] [Related]
9. How to manage rheumatic patients during the coronavirus pandemic.
Parisi S; Ditto MC; Finucci A; Fusaro E
Panminerva Med; 2020 Sep; 62(3):176-177. PubMed ID: 32343511
[No Abstract] [Full Text] [Related]
10. COVID-19 revisiting inflammatory pathways of arthritis.
Schett G; Manger B; Simon D; Caporali R
Nat Rev Rheumatol; 2020 Aug; 16(8):465-470. PubMed ID: 32561873
[TBL] [Abstract][Full Text] [Related]
11. COVID-19: consider cytokine storm syndromes and immunosuppression.
Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
[No Abstract] [Full Text] [Related]
12. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
[No Abstract] [Full Text] [Related]
13. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.
Georgiev T
Rheumatol Int; 2020 May; 40(5):825-826. PubMed ID: 32232552
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.
Pontali E; Volpi S; Antonucci G; Castellaneta M; Buzzi D; Tricerri F; Angelelli A; Caorsi R; Feasi M; Calautti F; Castagnola E; Rollandi GA; Ravelli A; Cassola G; Gattorno M
J Allergy Clin Immunol; 2020 Jul; 146(1):213-215. PubMed ID: 32437739
[No Abstract] [Full Text] [Related]
15. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.
Monti S; Balduzzi S; Delvino P; Bellis E; Quadrelli VS; Montecucco C
Ann Rheum Dis; 2020 May; 79(5):667-668. PubMed ID: 32241793
[No Abstract] [Full Text] [Related]
16. Old and new antirheumatic drugs for the treatment of COVID-19.
Benucci M; Damiani A; Infantino M; Manfredi M; Quartuccio L
Joint Bone Spine; 2020 May; 87(3):195-197. PubMed ID: 32321635
[No Abstract] [Full Text] [Related]
17. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
[TBL] [Abstract][Full Text] [Related]
18. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.
Conti A; Lasagni C; Bigi L; Pellacani G
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e360-e361. PubMed ID: 32379913
[No Abstract] [Full Text] [Related]
19. Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab.
Dolinger MT; Person H; Smith R; Jarchin L; Pittman N; Dubinsky MC; Lai J
J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):153-155. PubMed ID: 32452979
[TBL] [Abstract][Full Text] [Related]
20. Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.
Delaleu J; Deniau B; Battistella M; de Masson A; Bensaid B; Jachiet M; Lazaridou I; Bagot M; Bouaziz JD;
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2777-2779.e1. PubMed ID: 32525093
[No Abstract] [Full Text] [Related]
[Next] [New Search]
